The global hemostasis diagnostics market size values USD 3.98 billion in 2020 and expected to reach USD 7.26 billion in 2027 at a CAGR of 9.1% during the forecast period 2021-2027. Hemostasis diagnostics are the devices used to determine the hemostatic defects, which cause excessive bleeding. Hemostasis is defined as the stopping or slowing the blood flow from the damaged blood vessel. During the hemostasis, blood changes from liquid state to the gelatinous state. Hemostasis maintained in the body by three mechanisms namely, blood coagulation, platelet plug formation, and vasoconstriction. Hemostasis diagnostics may help to predict the cause of bleeding during surgery by identifying the hemostatic defects in patients. Different types of tests such as prothrombin test, activated clotting time, platelet function, and other coagulation tests are carried to identify the hemostasis defects. The market is growing at a significant rate due to rise in the prevalence of trauma condition and various surgeries around the globe. Moreover, the rise in prevalence of cardiovascular diseases, cancer, and diabetes also expected to propel the market. Furthermore, acquisitions and mergers, collaborations, test approvals, and launchings are the strategies followed by the companies for increasing their revenue share. For instance, in January 2017, Instrumentation Laboratory, a subsidiary of Werfen has acquired Accriva Diagnostics for the expansion of its hemostasis testing portfolio. In addition, in June 2017, Grifols and Beckman Coulter entered into a distribution agreement for the distribution of Grifol’s hemostasis instruments, consumables, and reagents around the globe.